Adaptive Biotechnologies (ADPT) revenue

Revenue · fiscal 2025
$276.98M

Adaptive Biotechnologies (ADPT) reported revenue of $276.98M in fiscal 2025 (the year ended December 31, 2025). That is 54.8% higher than the $178.96M of fiscal 2024. Figures as of 18 Nov 2026, 09:08 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$276.98M
Change on fiscal 2024
+54.8%
Growth, 5 years
+23.0% a year
Highest on record
$276.98Mfiscal 2025
Lowest on record
$38.45Mfiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Adaptive Biotechnologies revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 23.0% a year. Across the 9 fiscal years on record (2017–2025), the highest was $276.98M in fiscal 2025 and the lowest $38.45M in fiscal 2017.

History · 9 fiscal years

Revenue by fiscal year

Adaptive Biotechnologies revenue, year by year

Adaptive Biotechnologies (ADPT) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$276.98M 54.8% up
2024$178.96M 5.1% up
2023$170.28M 8.1% down
2022$185.31M 20.1% up
2021$154.34M 56.9% up
2020$98.38M 15.6% up
2019$85.07M 52.8% up
2018$55.66M 44.8% up
2017$38.45M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Adaptive Biotechnologies and comparable companies
CompanyRevenueFiscal year
Dianthus Therapeutics DNTH$2.04M2025
MiniMed Group MMED$3.10B2026
Adaptive Biotechnologies ADPT$276.98M2025
Heartflow HTFL$176.03M2025
CRISPR Therapeutics CRSP$35.00M2024

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ADPT

Adaptive Biotechnologies, figure by figure

Adaptive Biotechnologies (ADPT) overview: price, valuation and scorecardAll health care companies by market value

Adaptive Biotechnologies revenue: questions and answers

What is Adaptive Biotechnologies's revenue?

Adaptive Biotechnologies (ADPT) reported revenue of $276.98M in fiscal 2025 (the year ended December 31, 2025). That is 54.8% higher than the $178.96M of fiscal 2024.

What is the growth rate of Adaptive Biotechnologies's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 23.0% a year.

What are the highest and lowest revenue figures on record for Adaptive Biotechnologies?

Across the 9 fiscal years on record (2017–2025), the highest was $276.98M in fiscal 2025 and the lowest $38.45M in fiscal 2017.

How is Adaptive Biotechnologies's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Adaptive Biotechnologies it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Adaptive Biotechnologies (ADPT) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/ADPT/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.